Latest Insider Transactions at Vertex Pharmaceuticals Inc (VRTX)
This section provides a real-time view of insider transactions for Vertex Pharmaceuticals Inc (VRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERTEX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERTEX PHARMACEUTICALS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2022
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,571
+8.88%
|
$1,018,505
$155.57 P/Share
|
|
Aug 10
2022
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
36
-0.27%
|
$10,800
$300.32 P/Share
|
|
Aug 10
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
180
-0.15%
|
$54,180
$301.17 P/Share
|
|
Aug 10
2022
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
64
+0.1%
|
$9,920
$155.57 P/Share
|
|
Aug 09
2022
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
1,400
-0.6%
|
$418,600
$299.68 P/Share
|
|
Aug 09
2022
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
946
-6.6%
|
$283,800
$300.0 P/Share
|
|
Aug 09
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
5,690
-4.32%
|
$1,707,000
$300.98 P/Share
|
|
Aug 09
2022
|
Stuart A Arbuckle EVP, COO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,926
+2.81%
|
$298,530
$155.57 P/Share
|
|
Aug 08
2022
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
621
-2.46%
|
$181,332
$292.97 P/Share
|
|
Aug 08
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,304
-0.71%
|
$380,768
$292.8 P/Share
|
|
Aug 08
2022
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,304
+3.37%
|
$243,848
$187.53 P/Share
|
|
Aug 01
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
766
-1.83%
|
$211,416
$276.62 P/Share
|
|
Jul 29
2022
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
621
-1.83%
|
$173,259
$279.58 P/Share
|
|
Jul 25
2022
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
132,079
-46.74%
|
$37,114,199
$281.39 P/Share
|
|
Jul 25
2022
|
Jeffrey M Leiden Executive Chairman |
BUY
Exercise of conversion of derivative security
|
Direct |
60,342
+30.97%
|
$5,491,122
$91.05 P/Share
|
|
Jul 19
2022
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
17,865
-9.43%
|
$5,145,120
$288.18 P/Share
|
|
Jul 19
2022
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,765
+15.13%
|
$3,037,815
$171.55 P/Share
|
|
Jun 24
2022
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
11,689
-9.52%
|
$3,401,499
$291.3 P/Share
|
|
May 31
2022
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
311
-0.62%
|
$84,281
$271.24 P/Share
|
|
May 18
2022
|
Suketu Upadhyay Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,558
+50.0%
|
-
|
|
May 17
2022
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Bona fide gift
|
Indirect |
1,672
-13.14%
|
-
|
|
May 16
2022
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
133
-0.18%
|
$33,516
$252.61 P/Share
|
|
May 16
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
133
-0.03%
|
$33,250
$250.37 P/Share
|
|
May 16
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
45
-0.02%
|
$11,340
$252.56 P/Share
|
|
May 04
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
36
-0.09%
|
$9,900
$275.09 P/Share
|
|
May 02
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
343
-0.11%
|
$88,837
$259.61 P/Share
|
|
May 02
2022
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
737
-1.66%
|
$190,883
$259.81 P/Share
|
|
May 02
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
320
-0.11%
|
$82,880
$259.66 P/Share
|
|
May 02
2022
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
306
-0.47%
|
$80,478
$263.98 P/Share
|
|
May 01
2022
|
Lloyd Carney Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,449
+17.46%
|
-
|
|
May 01
2022
|
Margaret G Mcglynn Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
921
-83.8%
|
-
|
|
May 01
2022
|
Sangeeta N. Bhatia Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,449
+17.91%
|
-
|
|
May 01
2022
|
Diana Mckenzie Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,449
+33.44%
|
-
|
|
May 01
2022
|
Diana Mckenzie Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,842
-56.21%
|
-
|
|
May 01
2022
|
Terrence C Kearney Director |
BUY
Grant, award, or other acquisition
|
Direct |
725
+9.98%
|
-
|
|
Apr 29
2022
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
766
-1.79%
|
$211,416
$276.17 P/Share
|
|
Apr 29
2022
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
547
-1.25%
|
$150,972
$276.17 P/Share
|
|
Apr 29
2022
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
120
-0.17%
|
$33,000
$275.7 P/Share
|
|
Apr 25
2022
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
327
-2.21%
|
$87,963
$269.25 P/Share
|
|
Apr 18
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-16.11%
|
$568,000
$284.68 P/Share
|
|
Apr 18
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 14
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-16.4%
|
$578,000
$289.45 P/Share
|
|
Apr 14
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 13
2022
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
15,789
-17.55%
|
$4,563,021
$289.04 P/Share
|
|
Apr 13
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-8.57%
|
$572,000
$286.7 P/Share
|
|
Apr 13
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 12
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-15.97%
|
$562,000
$281.17 P/Share
|
|
Apr 12
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|
|
Apr 11
2022
|
Yuchun Lee Director |
SELL
Open market or private sale
|
Direct |
2,000
-20.71%
|
$560,000
$280.67 P/Share
|
|
Apr 11
2022
|
Yuchun Lee Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+34.04%
|
$162,000
$81.54 P/Share
|